Department of Nutrition, Nutrition, and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz,Iran.
Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd,Iran.
Endocr Metab Immune Disord Drug Targets. 2021;21(11):2090-2098. doi: 10.2174/1871530321666210104145231.
Curcumin has demonstrated many pharmacological effects including antioxidants, anti-inflammation, eliminating free radicals, anti-tumor, lipid regulation, and anti-coagulation.
This study aimed to assess and compare the effects of curcumin and nano-curcumin on lipid profile, oxidative stress, and inflammatory factors related to patient's heart.
This randomized, double-blind, placebo-controlled clinical trial was conducted on 90 patients undergoing coronary elective angioplasty who were randomly divided into 3 groups. The doses administered for 8 weeks were a 500 mg capsule of curcumin daily for the first group and an 80 mg capsule of nano-curcumin for the second group. However, the placebo group received capsules like curcumin. Lipid profile, oxidative stress factors, and inflammatory markers were measured at the baseline and end of the experiment.
Statistically significant changes were observed in the total cholesterol (TC), triacylglycerol (TG) and low-density lipoprotein cholesterol (LDL-C) in the intervention groups to the control group (p<0.05). Curcumin and nano-curcumin supplementation also exhibited significant changes in plasma levels of total antioxidant capacity (TAC), malondialdehyde (MDA), Superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), high-sensitivity C-reactive protein (hs- CRP), Interleukin 1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) in comparison to the placebo (p<0.05). Furthermore, the nano-curcumin group compared to the curcumin group demonstrated significant changes (p<0.05) in TC, TG, SOD, MDA and TNF-α levels.
The effects of curcumin on nano formula may be better for cardiac patients due to its high bioavailability.
姜黄素具有多种药理作用，包括抗氧化、抗炎、清除自由基、抗肿瘤、调节血脂、抗凝等。
本研究旨在评估和比较姜黄素和纳米姜黄素对血脂谱、氧化应激和与患者心脏相关的炎症因子的影响。
这是一项随机、双盲、安慰剂对照的临床试验，共纳入 90 例接受选择性冠状动脉成形术的患者，随机分为 3 组。第 1 组给予 500mg 姜黄素胶囊，第 2 组给予 80mg 纳米姜黄素胶囊，第 3 组给予安慰剂胶囊，疗程为 8 周。在基线和实验结束时测量血脂谱、氧化应激因子和炎症标志物。
干预组的总胆固醇（TC）、三酰甘油（TG）和低密度脂蛋白胆固醇（LDL-C）与对照组相比均有统计学意义的变化（p<0.05）。姜黄素和纳米姜黄素补充剂也显著改变了血浆总抗氧化能力（TAC）、丙二醛（MDA）、超氧化物歧化酶（SOD）、谷胱甘肽过氧化物酶（GSH-Px）、高敏 C 反应蛋白（hs-CRP）、白细胞介素 1β（IL-1β）和肿瘤坏死因子-α（TNF-α）的水平，与安慰剂组相比（p<0.05）。此外，纳米姜黄素组与姜黄素组相比，TC、TG、SOD、MDA 和 TNF-α水平有显著变化（p<0.05）。
由于纳米姜黄素具有较高的生物利用度，其对心脏患者的作用可能优于姜黄素。
